论文部分内容阅读
本文利用福氏佐剂包裹化疗药５－Ｆｕ，制成５－Ｆｕ－ＦＣＡ，对其体内外释放进行了研究，与５－Ｆｕ注射液比较体内、体外均有明显缓释作用。并观察了５－Ｆｕ－ＦＣＡ对艾氏腹水瘤、Ｓ１８０肉瘤（腹水性）及Ｈ２２小鼠肝癌瘤（腹水性）、荷瘤鼠的抗瘤作用，发现于接种瘤株后第２日一次性注射５－Ｆｕ－ＦＣＡ（４ｍｇ／只），小鼠存活期显著延长，且每组均有２只完全治愈；与盐水ＦＣＡ、５－Ｆｕ组比较有显著差别（ｐ＜０．００１）。该研究为提高５－Ｆｕ治疗效果提供了一个新途径。
In this paper, 5-Fu was used to encapsulate the chemotherapeutic drug 5-Fu with Freund’s adjuvant to make 5-Fu-FCA. The release of 5-Fu-FCA was studied in vivo and in vitro. The anti-tumor effects of 5-Fu-FCA on Ehrlich ascites tumor, S180 sarcoma (ascites) and H22 mouse hepatoma (ascites) and tumor-bearing mice were observed. Injection of 5-Fu-FCA (4mg / only) significantly prolonged the survival of mice, and each group were completely cured in 2; compared with saline FCA, 5-Fu group was significantly different (p <0.001). This study provides a new way to improve the therapeutic effect of 5-Fu.